Literature DB >> 26205340

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Ignacio Melero1, David M Berman2, M Angela Aznar1, Alan J Korman3, José Luis Pérez Gracia1, John Haanen4.   

Abstract

Immunotherapy has now been clinically validated as an effective treatment for many cancers. There is tremendous potential for synergistic combinations of immunotherapy agents and for combining immunotherapy agents with conventional cancer treatments. Clinical trials combining blockade of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) may serve as a paradigm to guide future approaches to immuno-oncology combination therapy. In this Review, we discuss progress in the synergistic design of immune-targeting combination therapies and highlight the challenges involved in tailoring such strategies to provide maximal benefit to patients.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26205340     DOI： 10.1038/nrc3973

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  174 in total

1.  CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.

Authors:  Yu-Hwa Huang; Chen Zhu; Yasuyuki Kondo; Ana C Anderson; Amit Gandhi; Andrew Russell; Stephanie K Dougan; Britt-Sabina Petersen; Espen Melum; Thomas Pertel; Kiera L Clayton; Monika Raab; Qiang Chen; Nicole Beauchemin; Paul J Yazaki; Michal Pyzik; Mario A Ostrowski; Jonathan N Glickman; Christopher E Rudd; Hidde L Ploegh; Andre Franke; Gregory A Petsko; Vijay K Kuchroo; Richard S Blumberg
Journal:  Nature       Date:  2014-10-26       Impact factor: 49.962

2.  Requirement for CD70 in CD4+ Th cell-dependent and innate receptor-mediated CD8+ T cell priming.

Authors:  Vadim Y Taraban; Tania F Rowley; David F Tough; Aymen Al-Shamkhani
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

Review 3.  Effective tumor immunotherapy: start the engine, release the brakes, step on the gas pedal,...and get ready to face autoimmunity.

Authors:  Iñigo Tirapu; Guillermo Mazzolini; Mercedes Rodriguez-Calvillo; Ainhoa Arina; Belen Palencia; Izaskun Gabari; Ignacio Melero
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2002       Impact factor: 4.291

4.  The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.

Authors:  Lucy S K Walker; David M Sansom
Journal:  Nat Rev Immunol       Date:  2011-11-25       Impact factor: 53.106

5.  CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.

Authors:  Rong Rong Huang; Jason Jalil; James S Economou; Bartosz Chmielowski; Richard C Koya; Stephen Mok; Hooman Sazegar; Elizabeth Seja; Arturo Villanueva; Jesus Gomez-Navarro; John A Glaspy; Alistair J Cochran; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2011-05-10       Impact factor: 12.531

Review 6.  The CD4-like molecule LAG-3, biology and therapeutic applications.

Authors:  Sophie Sierro; Pedro Romero; Daniel E Speiser
Journal:  Expert Opin Ther Targets       Date:  2011-01       Impact factor: 6.902

7.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

8.  Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.

Authors:  Antoni Ribas; Begoña Comin-Anduix; James S Economou; Timothy R Donahue; Pilar de la Rocha; Lilah F Morris; Jason Jalil; Vivian B Dissette; Itsushi Peter Shintaku; John A Glaspy; Jesus Gomez-Navarro; Alistair J Cochran
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

9.  Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Authors:  Matthew M Gubin; Xiuli Zhang; Heiko Schuster; Etienne Caron; Jeffrey P Ward; Takuro Noguchi; Yulia Ivanova; Jasreet Hundal; Cora D Arthur; Willem-Jan Krebber; Gwenn E Mulder; Mireille Toebes; Matthew D Vesely; Samuel S K Lam; Alan J Korman; James P Allison; Gordon J Freeman; Arlene H Sharpe; Erika L Pearce; Ton N Schumacher; Ruedi Aebersold; Hans-Georg Rammensee; Cornelis J M Melief; Elaine R Mardis; William E Gillanders; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

10.  Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

Authors:  Antonio M Grimaldi; Ester Simeone; Diana Giannarelli; Paolo Muto; Sara Falivene; Valentina Borzillo; Francesca Maria Giugliano; Fabio Sandomenico; Antonella Petrillo; Marcello Curvietto; Assunta Esposito; Miriam Paone; Marco Palla; Giuseppe Palmieri; Corrado Caracò; Gennaro Ciliberto; Nicola Mozzillo; Paolo A Ascierto
Journal:  Oncoimmunology       Date:  2014-05-14       Impact factor: 8.110
View more
  232 in total

1.  A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy.

Authors:  Haidong Dong; Yiyi Yan; Roxana S Dronca; Svetomir N Markovic
Journal:  SOJ Immunol       Date:  2017-02-25

Review 2.  Polymeric microneedles for transdermal protein delivery.

Authors:  Yanqi Ye; Jicheng Yu; Di Wen; Anna R Kahkoska; Zhen Gu
Journal:  Adv Drug Deliv Rev       Date:  2018-01-31       Impact factor: 15.470

3.  Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.

Authors:  Alex B Blair; Lei Zheng
Journal:  Chin Clin Oncol       Date:  2017-06

4.  Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017.

Authors:  Peter L Stern
Journal:  Ther Adv Vaccines       Date:  2017-07-20

5.  Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production.

Authors:  Paurvi Shinde; Wenhai Liu; Antoine Ménoret; Andrew D Luster; Anthony T Vella
Journal:  J Leukoc Biol       Date:  2017-04-21       Impact factor: 4.962

6.  Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

Authors:  Shyril O'Steen; Damian J Green; Ajay K Gopal; Johnnie J Orozco; Aimee L Kenoyer; Yukang Lin; D Scott Wilbur; Donald K Hamlin; Darrell R Fisher; Mark D Hylarides; Theodore A Gooley; Amelia Waltman; Brian G Till; Oliver W Press
Journal:  Cancer Res       Date:  2017-05-31       Impact factor: 12.701

7.  Multi-organ Mapping of Cancer Risk.

Authors:  Liqin Zhu; David Finkelstein; Culian Gao; Lei Shi; Yongdong Wang; Dolores López-Terrada; Kasper Wang; Sarah Utley; Stanley Pounds; Geoffrey Neale; David Ellison; Arzu Onar-Thomas; Richard James Gilbertson
Journal:  Cell       Date:  2016-08-25       Impact factor: 41.582

Review 8.  Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.

Authors:  Jinfang Zhang; Fabin Dang; Junming Ren; Wenyi Wei
Journal:  Trends Biochem Sci       Date:  2018-10-01       Impact factor: 13.807

Review 9.  Not all cancers are created equal: Tissue specificity in cancer genes and pathways.

Authors:  Joy J Bianchi; Xin Zhao; Joseph C Mays; Teresa Davoli
Journal:  Curr Opin Cell Biol       Date:  2020-02-21       Impact factor: 8.382

10.  BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

Authors:  Hengrui Zhu; Fee Bengsch; Nikolaos Svoronos; Melanie R Rutkowski; Benjamin G Bitler; Michael J Allegrezza; Yuhki Yokoyama; Andrew V Kossenkov; James E Bradner; Jose R Conejo-Garcia; Rugang Zhang
Journal:  Cell Rep       Date:  2016-09-13       Impact factor: 9.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.